Enyo Pharma (France) has announced the closing of a €22M funding round in order to roll out its clinical program in Hepatitis B, its first target therapeutic area.
This Antiviral Biotech in Lyon is developing treatments against major human viruses, with the first two R&D programs being dedicated to the treatment of severe and seasonal influenza and chronic hepatitis B.
Viral infections represent a major public health and socioeconomic problem. According to the WHO, more than 350 million people with chronic hepatitis B infections are awaiting treatment. Current regimens (pegylated interferons and polymerase inhibitors) often fail to cure HBV and are life long treatments.
This particular investment is intended to help the company roll out its clinical hepatitis-B program more quickly. The company plans to conduct its molecules to phase II trials.
Jacky Vonderscher, President of Enyo Pharma (Left), explained that Enyo Pharma has a novel approach to disrupting the interaction between viral proteins and intra-cellular proteins, which prevents the virus from establishing itself.
Through this method, Enyo have also identified several new drug targets involved in the replication of severe forms of these viruses.
This discovery of compounds capable of changing the activity of these new targets opens up new therapeutic horizons that go far beyond virology.“
Rafaèle Tordjman, managing partner at Sofinnova, explained how this €22M round follows a seed funding, and so is the continuation of several major advances. Enyo Pharma has licensed several patents and developed a unique technology platform.
The [Enyo Pharma] team is ideally positioned to convert the growing virology market”
The late-stage pipeline for Hepatitis B an an indication in the market is weaker due to the lack of first-in-class and innovative products reaching late-stage clinical development.
So we hope for the best regarding Enyo Pharma’s pipeline, and I look forward to seeing the next milestones!
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.